March 9, 2006 (San Francisco) — The largest and arguably most complex risk-management program ever undertaken by the US Food and Drug Administration is sparking a commensurate measure of controversy — ...
It was determined that these changes would help reduce the burden on patients and providers while ensuring the benefits of isotretinoin treatment continue to outweigh the risks of embryo-fetal ...
Please provide your email address to receive an email when new articles are posted on . The AAD and the FDA recommended changes to the iPledge system, but none have yet taken place. The AAD’s iPledge ...
WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- The FDA agreed to require important American Academy of Dermatology's (AAD) recommended changes to the iPLEDGE program that will alleviate administrative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback